Lorlatinib in Focus: Survival, Brain Metastases, and Beyond

EP: 1.The Evolution of ALK+ NSCLC Care

Now Viewing

EP: 2.Lorlatinib in Focus: Survival, Brain Metastases, and Beyond

EP: 3.Choosing Wisely: Insights from an MAIC and eXalt3

EP: 4.Applying Trial Data to Real-World Practice in ALK+ NSCLC

EP: 5.Key Differences Among ALK Inhibitors

EP: 6.Navigating ALK Inhibitor Toxicities

EP: 7.Lorlatinib’s Unique Challenges: Managing Cognitive and Metabolic AEs

EP: 8.Long-Term Success: Educating and Supporting Patients on ALK Inhibitors

EP: 9.Equitable Access to Molecular Testing and Treatment Prioritization

EP: 10.Next Steps: Post-Frontline Therapies and Resistance in ALK+ NSCLC

EP: 11.Education and Support After Progression ALK Inhibitors

EP: 12.Looking Ahead: The Next Frontier in ALK+ NSCLC Therapy

Panel Introduction

CROWN Trial and Lorlatinib Treatment in ALK+ Metastatic NSCLC

• Discussion focused on the 5-year data from the CROWN trial evaluating lorlatinib for ALK-positive metastatic NSCLC
• Analysis of how these long-term outcomes have influenced the current treatment paradigm
• Comparison of clinical trial results with real-world outcomes observed by treating physicians

Key Treatment Considerations

• Long-term survival benefits and durability of response with lorlatinib
• Emphasis on efficacy against brain metastases, which are common in ALK+ NSCLC
• Cost-effectiveness evaluations when selecting frontline treatment options

Clinical Implementation

• Real-world efficacy and safety profile of lorlatinib compared to clinical trial results
• Practical considerations in implementing treatments based on CROWN trial evidence
• Balance between efficacy outcomes and economic considerations in treatment decisions

Notable Insights

• Dr. Dietrich was asked to describe the CROWN trial design and elaborate on how the 5-year data has influenced the treatment landscape for ALK+ metastatic NSCLC, particularly regarding survival outcomes and response durability.
• Dr. Lovly addressed the unique long-term outcomes with lorlatinib, especially its efficacy against brain metastases, and discussed the complex balance between cost considerations and clinical efficacy when making frontline treatment decisions.
• Castronovo provided perspective on real-world clinical experience with lorlatinib, comparing observed efficacy and safety profiles with those reported in the controlled CROWN trial setting.